Melanoma News and Research

Latest Melanoma News and Research

Delcath Systems to present abstract at ILCA Annual Conference

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that Dr. James F. Pingpank, Associate Professor of Surgery for the University of Pittsburgh School of Medicine will present an abstract at the International Liver Cancer Association's (ILCA) Third Annual Conference on Saturday, September 5, 2009 in Milan, Italy.

4 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

Delcath Systems begins operations facility in Queensbury, New York

Delcath Systems, Inc. (Nasdaq: DCTH), a Manhattan headquartered medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it has signed a three-year lease with the option to buy on a 10,000 square foot facility in Queensbury, New York in which it plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System.

3 Sep 2009

MIPI to sub-license the Onalta brand 90-Y edotreotide radiotherapeutic

Molecular Insight Pharmaceuticals, Inc. today announced that it has completed an agreement to sub-license its Onalta™ brand 90-Y edotreotide radiotherapeutic in certain countries in Europe, the Middle East, North Africa, Russia and Turkey to BioMedica Life Sciences, S.A., Athens, Greece.

3 Sep 2009

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.

2 Sep 2009

ZymoGenetics to provide company updates at upcoming investor conferences

ZymoGenetics, Inc. announced today that senior executives will provide updates on company activities at two upcoming investor conferences.

2 Sep 2009

AAD urges Americans to remind grandparents to perform skin self-examination

Sunday, September 13, is National Grandparents Day, and the American Academy of Dermatology (Academy) recommends that people lovingly remind their grandparents to perform a skin self-examination.

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

Leading experts in health and health care reform to take part in symposium

With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation’s leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.

29 Aug 2009

Novel methodology developed to extract microRNAs from cancer tissues

Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.

28 Aug 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

27 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

NY-ESO-1 recombinant proteins to be used in clinical trials for treating melanoma and ovarian cancer

The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein-a cancer vaccine-that will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

21 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

Antigenics’ Oncophage cancer vaccine trial starts enrolling patients

Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage (vitespen) in combination with the standard of care - radiation therapy plus Temodar (temozolomide) - for newly diagnosed glioma patients.

13 Aug 2009

Giant pituitary adenoma can be safely removed through nasal route

It’s even worse than being told you have a brain tumor: having a tumor so large, it’s in a category all its own. Giant pituitary adenoma is a so-called “benign” tumor that can cause visual loss and impair many of the body’s most basic functions. But fortunately, even the largest of these giant tumors—which can grow to the size of an egg and invade nearby structures--can be treated effectively using a multimodality approach starting with minimally invasive surgery through the nose, according to a new study at the John Wayne Cancer Institute at Saint John’s Health Center.

12 Aug 2009

Neoprobe announces Q2 financials

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.

12 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009